The final, formatted version of the article will be published soon.
ORIGINAL RESEARCH article
Front. Immunol.
Sec. T Cell Biology
Volume 16 - 2025 |
doi: 10.3389/fimmu.2025.1539265
Use of a universal targeting CAR T cell to simultaneously kill cancer cells and cancer-associated fibroblasts
Provisionally accepted- 1 Department of Chemistry, Purdue Institute for Drug Discovery, Purdue University, West Lafayette, United States
- 2 Umoja Biopharma, Seattle, Washington, United States
CAR T cells therapies have demonstrated success in treating hematologic malignancies, but have proven less effective in eradicating solid tumors. While suppressive immune cells may contribute to reduced CAR T cell efficacies in malignant masses, cancer-associated fibroblasts (CAFs) are also believed to facilitate tumor survival by secreting growth factors, immunosuppressive cytokines, and extracellular matrix components that inhibit drug and immune cell filtration and facilitate metastasis. In an effort to eliminate both CAFs and cancer cells simultaneously, we have employed a universal CAR T cell that can attack both cell types when supplemented with appropriate bispecific adapters. We show here that tumor regression is indeed enhanced when CAR T cells are directed to concurrently kill both cancer cells and CAFs. We further demonstrate that simultaneous targeting of both cell types enhances CAR T cell proliferation, activation, tumor infiltration, and tumor distribution relative to targeting only a single cell type. Because all of these benefits are achieved in both cold and hot tumors without significant toxicity, we conclude that use of a universal CAR T cell in combination with multiple bispecific adapters can provide a safe, potent, cost-effective, and scalable alternative to the treatment of solid tumors with conventional CAR T cells.
Keywords: Universal CAR T cells, Tumor Microenvironment, Cancer-associated fibroblasts (CAFs), solid tumors, fibroblast activation protein (FAP)
Received: 04 Dec 2024; Accepted: 30 Jan 2025.
Copyright: © 2025 Huang, Zheng, Sudarshan, Mukkamala, Srinivasarao, Sardesai, Yang, Chu and Low. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Philip S Low, Department of Chemistry, Purdue Institute for Drug Discovery, Purdue University, West Lafayette, United States
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.